Glück Conviction Score™ ⓘ
BCAX
Bicara Therapeutics Inc.
ⓘ
Eingeschränkte Aussagekraft — erst 63 % der Signal-Gewichte sind mit Daten unterlegt.
Effektiv: Schwach
Mittel
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
42,3
25 neu, 61 erhöht, 301,7M $ netto
Aktivist
33,1
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bärisch | 10 % | 21.72 | -0.1 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 17.67 | +22.8 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 20.92 | EMA50: 20.86 | |
| MACD-Histogramm | Bullisch | 10 % | 0.095 | Bullisch | |
| RSI(14) | Neutral | 10 % | 55.1 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 69.7 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 15.9 | +DI: 22.3 / −DI: 19.0 | |
| Z-Score(60) | Neutral | 5 % | 0.28 | In Range | |
| 52W-Position | Bullisch | 5 % | 84.8 % | Hoch 24.01 / Tief 8.71 | |
| Bollinger(20,2σ) | Bärisch | 5 % | 81.2 % | Upper 22.28 / Mid 20.70 / Lower 19.12 | |
| LinReg-Slope(60) | Neutral | 10 % | +0.0129 | R²=0.02 / annualisiert +15.3 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -9.200 | 20,42 | -187.883,32 | -75,4% | |
| 2026-05-18 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -12.022 | 19,96 | -239.981,96 | -96,3% | |
| 2026-05-18 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -2.978 | 20,35 | -60.596,64 | -24,3% | |
| 2026-05-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8.000 | 20,29 | -162.335,20 | -65,1% | |
| 2026-05-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.500 | 20,29 | -91.313,55 | -36,6% | |
| 2026-04-27 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -5.500 | 22,88 | -125.830,10 | -50,5% | |
| 2026-04-21 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -9.200 | 23,00 | -211.613,80 | -84,9% | |
| 2026-04-20 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -15.000 | 23,61 | -354.145,50 | -142,0% | |
| 2026-04-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8.000 | 23,01 | -184.058,40 | -73,8% | |
| 2026-04-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.500 | 23,01 | -103.532,85 | -41,5% | |
| 2026-03-25 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -5.500 | 18,95 | -104.229,40 | -41,8% | |
| 2026-03-23 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -9.200 | 18,52 | -170.348,12 | -68,3% | |
| 2026-03-20 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -1.596 | 18,95 | -30.246,27 | -12,1% | |
| 2026-03-19 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -6.905 | 18,78 | -129.704,90 | -52,0% | |
| 2026-03-18 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -6.499 | 18,84 | -122.414,51 | -49,1% | |
| 2026-03-16 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8.000 | 19,66 | -157.256,80 | -63,1% | |
| 2026-03-16 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.500 | 19,66 | -88.456,95 | -35,5% | |
| 2026-03-09 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -36.766 | 19,17 | -704.657,16 | -282,6% | |
| 2026-03-06 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -3.817 | 18,75 | -71.571,80 | -28,7% | |
| 2026-03-05 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -1.786 | 18,74 | -33.464,10 | -13,4% | |
| 2026-03-04 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -16.300 | 18,52 | -301.920,01 | -121,1% | |
| 2026-03-04 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -2.631 | 18,73 | -49.288,63 | -19,8% | |
| 2026-03-04 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -2.963 | 18,25 | -54.061,71 | -21,7% | |
| 2026-03-03 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -200 | 18,45 | -3.690,00 | -1,5% | |
| 2026-03-03 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -13.555 | 18,22 | -246.909,75 | -99,0% | |
| 2026-03-03 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -12.892 | 18,16 | -234.158,69 | -93,9% | |
| 2026-03-03 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.500 | 18,16 | -81.733,95 | -32,8% | |
| 2026-02-26 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Purchase | 300.000 | 16,00 | 4.800.000,00 | +1925,2% | |
| 2026-02-25 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -523 | 18,04 | -9.434,66 | -3,8% | |
| 2026-02-25 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -3.108 | 18,04 | -56.066,77 | -22,5% | |
| 2026-01-22 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -1.882 | 18,15 | -34.162,44 | -13,7% | |
| 2026-01-22 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -3.828 | 18,10 | -69.295,99 | -27,8% | |
| 2026-01-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -149 | 18,02 | -2.684,98 | -1,1% | |
| 2025-12-22 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -9.200 | 18,31 | -168.491,56 | -67,6% | |
| 2025-12-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.500 | 18,68 | -84.077,10 | -33,7% | |
| 2025-12-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8.000 | 18,68 | -149.470,40 | -60,0% | |
| 2025-11-25 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -906 | 18,84 | -17.071,21 | -6,8% | |
| 2025-11-25 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -4.594 | 18,84 | -86.561,99 | -34,7% | |
| 2025-11-24 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -41.163 | 18,86 | -776.428,85 | -311,4% | |
| 2025-11-24 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -17.795 | 18,55 | -330.093,69 | -132,4% | |
| 2025-11-24 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -5.500 | 18,45 | -101.475,00 | -40,7% | |
| 2025-11-21 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -605 | 18,15 | -10.980,75 | -4,4% | |
| 2025-11-21 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8.000 | 18,05 | -144.376,00 | -57,9% | |
| 2025-11-21 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.500 | 18,05 | -81.211,50 | -32,6% | |
| 2025-10-16 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -24.103 | 18,83 | -453.760,67 | -182,0% | |
| 2025-10-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8.000 | 18,16 | -145.243,20 | -58,3% | |
| 2025-10-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4.500 | 18,16 | -81.699,30 | -32,8% | |
| 2025-10-15 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -13.289 | 18,84 | -250.391,34 | -100,4% | |
| 2025-10-13 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -11.445 | 18,92 | -216.545,12 | -86,9% | |
| 2025-10-09 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -22.000 | 18,45 | -405.900,00 | -162,8% | |
| 2025-10-09 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -6.415 | 18,23 | -116.931,34 | -46,9% | |
| 2025-10-08 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -5.627 | 18,21 | -102.456,42 | -41,1% | |
| 2025-10-07 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -2.900 | 18,06 | -52.371,39 | -21,0% | |
| 2025-10-07 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -18.244 | 18,22 | -332.385,61 | -133,3% | |
| 2025-10-07 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8.000 | 18,06 | -144.472,80 | -57,9% | |
| 2025-10-06 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -15.600 | 18,06 | -281.665,80 | -113,0% | |
| 2025-10-06 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -6.514 | 18,17 | -118.356,12 | -47,5% | |
| 2025-10-06 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -24.000 | 18,06 | -433.332,00 | -173,8% | |
| 2025-09-29 | Meisner Lara | Officer, Chief Legal Officer | Open Market Sale | -33.807 | 14,75 | -498.653,25 | -200,0% | |
| 2025-09-15 | Meisner Lara | Officer, Chief Legal Officer | Open Market Sale | -15.829 | 11,49 | -181.875,21 | -72,9% | |
| 2025-06-16 | Meisner Lara | Officer, Chief Legal Officer | Open Market Sale | -15.829 | 10,43 | -165.096,47 | -66,2% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 7.255.993 | 6.955.993 | 300.000 | 144.321.701 | Aufgestockt | +4,3% | |
| Siren, L.L.C. | 5.802.970 | 5.216.969 | 586.001 | 115.421.073 | Aufgestockt | +11,2% | |
| Vestal Point Capital, LP | 5.425.000 | 3.575.000 | 1.850.000 | 107.903.250 | Aufgestockt | +51,7% | |
| Deep Track Capital, LP | 4.062.500 | 2.614.004 | 1.448.496 | 80.803.125 | Aufgestockt | +55,4% | |
| JANUS HENDERSON GROUP PLC | 3.339.218 | 2.646.285 | 692.933 | 66.350.262 | Aufgestockt | +26,2% | |
| Red Tree Management, LLC | 3.170.509 | 3.170.509 | 0 | 63.061.424 | Unverändert | 0,0% | |
| TPG GP A, LLC | 3.010.425 | 3.010.425 | 0 | 59.877.353 | Unverändert | 0,0% | |
| BlackRock, Inc. | 2.843.707 | 2.528.451 | 315.256 | 56.561.328 | Aufgestockt | +12,5% | |
| Omega Fund Management, LLC | 2.392.150 | 2.204.650 | 187.500 | 47.579.864 | Aufgestockt | +8,5% | |
| Royalty Pharma Sub-Manager, LLC | 2.388.150 | 1.263.150 | 1.125.000 | 46.688.333 | Aufgestockt | +89,1% | |
| FMR LLC | 2.100.929 | 3.347.223 | -1.246.294 | 41.787.477 | Reduziert | -37,2% | |
| VANGUARD GROUP INC | 2.186.150 | 0 | 2.186.150 | 36.792.904 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.774.220 | 0 | 1.774.220 | 35.289.236 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 1.726.242 | 796.858 | 929.384 | 34.334.954 | Aufgestockt | +116,6% | |
| FRANKLIN RESOURCES INC | 1.621.643 | 1.620.025 | 1.618 | 32.254.484 | Aufgestockt | +0,1% | |
| STATE STREET CORP | 1.419.388 | 1.649.537 | -230.149 | 28.231.627 | Reduziert | -14,0% | |
| Jones Hill Capital LP | 1.260.136 | 0 | 1.260.136 | 25.064.105 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 830.906 | 811.400 | 19.506 | 16.530.951 | Aufgestockt | +2,4% | |
| FIL Ltd | 679.904 | 758.493 | -78.589 | 13.523.291 | Reduziert | -10,4% | |
| ORBIMED ADVISORS LLC | 667.300 | 209.100 | 458.200 | 13.272.597 | Aufgestockt | +219,1% | |
| ACORN CAPITAL ADVISORS, LLC | 643.382 | 643.382 | 0 | 12.796.860 | Unverändert | 0,0% | |
| Aisling Capital Management LP | 568.919 | 568.919 | 0 | 11.315.799 | Unverändert | 0,0% | |
| GOLDMAN SACHS GROUP INC | 558.964 | 552.331 | 6.633 | 11.117.794 | Aufgestockt | +1,2% | |
| Palo Alto Investors LP | 550.408 | 298.575 | 251.833 | 10.947.615 | Aufgestockt | +84,3% | |
| Rock Springs Capital Management LP | 489.095 | 429.095 | 60.000 | 9.728.100 | Aufgestockt | +14,0% | |
| NAN FUNG TRINITY (HK) Ltd | 427.885 | 372.385 | 55.500 | 8.510.633 | Aufgestockt | +14,9% | |
| DAFNA Capital Management LLC | 421.733 | 261.583 | 160.150 | 8.388.269 | Aufgestockt | +61,2% | |
| MORGAN STANLEY | 421.219 | 109.456 | 311.763 | 8.378.047 | Aufgestockt | +284,8% | |
| Ensign Peak Advisors, Inc | 401.444 | 401.444 | 0 | 7.984.721 | Unverändert | 0,0% | |
| BANK OF AMERICA CORP /DE/ | 327.989 | 335.682 | -7.693 | 6.523.702 | Reduziert | -2,3% | |
| Clearbridge Investments, LLC | 289.221 | 298.762 | -9.541 | 5.752.600 | Reduziert | -3,2% | |
| D. E. Shaw & Co., Inc. | 276.943 | 136.522 | 140.421 | 5.508.396 | Aufgestockt | +102,9% | |
| TD ASSET MANAGEMENT INC | 269.718 | 244.626 | 25.092 | 5.364.691 | Aufgestockt | +10,3% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 263.985 | 272.145 | -8.160 | 5.250.662 | Reduziert | -3,0% | |
| NORTHERN TRUST CORP | 255.571 | 237.107 | 18.464 | 5.083.308 | Aufgestockt | +7,8% | |
| Candriam S.C.A. | 238.822 | 0 | 238.822 | 4.750.170 | Neu | +100,0% | |
| Hudson Bay Capital Management LP | 233.703 | 150.000 | 83.703 | 4.648.353 | Aufgestockt | +55,8% | |
| Woodline Partners LP | 232.690 | 232.690 | 0 | 4.628.204 | Unverändert | 0,0% | |
| UBS Group AG | 179.491 | 192.191 | -12.700 | 3.570.076 | Reduziert | -6,6% | |
| MILLENNIUM MANAGEMENT LLC | 156.702 | 434.699 | -277.997 | 3.116.803 | Reduziert | -64,0% | |
| DEUTSCHE BANK AG\ | 131.656 | 128.626 | 3.030 | 2.618.637 | Aufgestockt | +2,4% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 118.544 | 91.493 | 27.051 | 2.357.840 | Aufgestockt | +29,6% | |
| Atle Fund Management AB | 1.169.634 | 111.363 | 1.058.271 | 2.315.235 | Aufgestockt | +950,3% | |
| Napean Trading & Investment Co (Singapore) PTE Ltd | 113.780 | 113.780 | 0 | 2.263.084 | Unverändert | 0,0% | |
| DIMENSIONAL FUND ADVISORS LP | 109.261 | 40.934 | 68.327 | 2.170.202 | Aufgestockt | +166,9% | |
| Walleye Capital LLC | 108.008 | 0 | 108.008 | 2.148.279 | Neu | +100,0% | |
| Burkehill Global Management, LP | 100.000 | 0 | 100.000 | 1.989.000 | Neu | +100,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 90.285 | 98.918 | -8.633 | 1.795.769 | Reduziert | -8,7% | |
| TWO SIGMA INVESTMENTS, LP | 89.881 | 98.481 | -8.600 | 1.787.733 | Reduziert | -8,7% | |
| Soleus Capital Management, L.P. | 100.000 | 0 | 100.000 | 1.683.000 | Neu | +100,0% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 7.255.993 | 6.955.993 | +4,3% | 144.321.701 | 11,80 |
| Siren, L.L.C. | 5.802.970 | 5.216.969 | +11,2% | 115.421.073 | 9,44 |
| Vestal Point Capital, LP | 5.425.000 | 3.575.000 | +51,7% | 107.903.250 | 8,82 |
| Deep Track Capital, LP | 4.062.500 | 2.614.004 | +55,4% | 80.803.125 | 6,61 |
| JANUS HENDERSON GROUP PLC | 3.339.218 | 2.646.285 | +26,2% | 66.350.262 | 5,43 |
| Red Tree Management, LLC | 3.170.509 | 3.170.509 | 0,0% | 63.061.424 | 5,16 |
| TPG GP A, LLC | 3.010.425 | 3.010.425 | 0,0% | 59.877.353 | 4,90 |
| BlackRock, Inc. | 2.843.707 | 2.528.451 | +12,5% | 56.561.328 | 4,62 |
| Omega Fund Management, LLC | 2.392.150 | 2.204.650 | +8,5% | 47.579.864 | 3,89 |
| Royalty Pharma Sub-Manager, LLC | 2.388.150 | 1.263.150 | +89,1% | 46.688.333 | 3,82 |
| FMR LLC | 2.100.929 | 3.347.223 | -37,2% | 41.787.477 | 3,42 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.774.220 | 0 | +100,0% | 35.289.236 | 2,89 |
| CITADEL ADVISORS LLC | 1.726.242 | 796.858 | +116,6% | 34.334.954 | 2,81 |
| FRANKLIN RESOURCES INC | 1.621.643 | 1.620.025 | +0,1% | 32.254.484 | 2,64 |
| STATE STREET CORP | 1.419.388 | 1.649.537 | -14,0% | 28.231.627 | 2,31 |
| Jones Hill Capital LP | 1.260.136 | 0 | +100,0% | 25.064.105 | 2,05 |
| GEODE CAPITAL MANAGEMENT, LLC | 830.906 | 811.400 | +2,4% | 16.530.951 | 1,35 |
| FIL Ltd | 679.904 | 758.493 | -10,4% | 13.523.291 | 1,11 |
| ORBIMED ADVISORS LLC | 667.300 | 209.100 | +219,1% | 13.272.597 | 1,09 |
| ACORN CAPITAL ADVISORS, LLC | 643.382 | 643.382 | 0,0% | 12.796.860 | 1,05 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 148 | 76,9 | 1.342 |
| 31.12.2025 | ✓ | 140 | 59,3 | 933 |
| 30.09.2025 | ✓ | 114 | 50,7 | 20.075 |
| 30.06.2025 | ✓ | 106 | 51,0 | 11.816 |
| 31.03.2025 | ✓ | 91 | 52,9 | 14.052 |
| 31.12.2024 | ✓ | 84 | 48,5 | 16.707 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| Royalty Pharma Sub-Manager, LLC | 1.263.150 | 45.864.977 |
| JANUS HENDERSON GROUP PLC | 2.646.285 | 44.484.051 |
| FRANKLIN RESOURCES INC | 1.620.025 | 27.265.020 |
| CITADEL ADVISORS LLC | 796.858 | 13.411.120 |
| Ensign Peak Advisors, Inc | 401.444 | 6.756.303 |
| Palo Alto Investors LP | 298.575 | 5.025.017 |
| ORBIMED ADVISORS LLC | 209.100 | 3.519.153 |
| Hudson Bay Capital Management LP | 150.000 | 2.524.500 |
| D. E. Shaw & Co., Inc. | 136.522 | 2.297.665 |
| JANE STREET GROUP, LLC | 105.183 | 1.770.230 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 3.236.595 | 2.771.868 | +596.5 % | 54.472 |
| STATE STREET CORP | 1.649.537 | 1.059.260 | +179.5 % | 27.761.708 |
| FMR LLC | 3.347.223 | 648.862 | +24.0 % | 56.333.763 |
| GOLDMAN SACHS GROUP INC | 552.331 | 319.570 | +137.3 % | 9.295.731 |
| ALGERT GLOBAL LLC | 318.269 | 300.679 | +1709.4 % | 5.356 |
| BlackRock, Inc. | 2.528.451 | 216.662 | +9.4 % | 42.553.826 |
| Deep Track Capital, LP | 2.614.004 | 187.347 | +7.7 % | 43.993.687 |
| UBS Group AG | 192.191 | 94.829 | +97.4 % | 3.234.575 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 91.493 | 78.493 | +603.8 % | 1.539.827 |
| CITIGROUP INC | 66.697 | 66.041 | +10067.2 % | 1.122.511 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| Vestal Point Capital, LP | 3.575.000 | -1.525.000 | -29.9 % | 60.167.250 |
| MILLENNIUM MANAGEMENT LLC | 434.699 | -580.193 | -57.2 % | 7.315.984 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.559.535 | -195.876 | -11.2 % | 26.248 |
| Napean Trading & Investment Co (Singapore) PTE Ltd | 113.780 | -162.162 | -58.8 % | 1.914.917 |
| BANK OF AMERICA CORP /DE/ | 335.682 | -120.939 | -26.5 % | 5.649.529 |
| Woodline Partners LP | 232.690 | -116.000 | -33.3 % | 3.916.173 |
| Atle Fund Management AB | 111.363 | -92.392 | -45.3 % | 1.874.239 |
| DAFNA Capital Management LLC | 261.583 | -55.418 | -17.5 % | 4.402.442 |
| FIL Ltd | 758.493 | -45.260 | -5.6 % | 12.765.437 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 98.918 | -27.884 | -22.0 % | 1.601.615 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 15.05.2026 | JANUS HENDERSON GROUP PLC | Passiv (13G) | 5,10 % | 3.339.218 | Neu | |
| 15.05.2026 | David Kroin | Passiv (13G/A) | 6,21 % | 4.062.500 | +1,19 pp | |
| 15.05.2026 | Deep Track Biotechnology Master Fund, Ltd. | Passiv (13G/A) | 6,21 % | 4.062.500 | +1,19 pp | |
| 15.05.2026 | Deep Track Capital, LP | Passiv (13G/A) | 6,21 % | 4.062.500 | +1,19 pp | |
| 15.05.2026 | Vestal Point Capital, LP | Passiv (13G/A) | 8,30 % | 5.425.000 | +1,80 pp | |
| 15.05.2026 | Ryan Wilder | Passiv (13G/A) | 8,30 % | 5.425.000 | +1,80 pp | |
| 09.05.2026 | Red Tree Venture Fund, L.P. | Passiv (13G/A) | 4,80 % | 3.170.509 | -1,00 pp | |
| 09.05.2026 | Red Tree GP, LLC | Passiv (13G/A) | 4,80 % | 3.170.509 | -1,00 pp | |
| 09.05.2026 | Heath Lukatch | Passiv (13G/A) | 4,80 % | 3.170.509 | -1,00 pp | |
| 06.05.2026 | FMR LLC | Passiv (13G/A) | 3,20 % | 2.100.929 | -2,90 pp | |
| 06.05.2026 | Abigail P. Johnson | Passiv (13G/A) | 3,20 % | 2.100.929 | -2,90 pp | |
| 08.04.2026 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 10,10 % | 6.605.780 | +4,20 pp | |
| 02.03.2026 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 7,30 % | 4.603.418 | -0,60 pp | |
| 02.03.2026 | RA Capital Management, L.P. | Aktivist (13D/A) | 11,50 % | 7.279.739 | -1,30 pp | |
| 02.03.2026 | Rajeev Shah | Aktivist (13D/A) | 11,50 % | 7.279.739 | -1,30 pp | |
| 02.03.2026 | Peter Kolchinsky | Aktivist (13D/A) | 11,50 % | 7.279.739 | -1,30 pp | |
| 17.02.2026 | T. Rowe Price Investment Management, Inc. | Passiv (13G) | 5,90 % | 3.236.595 | Neu | |
| 17.02.2026 | Ryan Wilder | Passiv (13G/A) | 6,50 % | 3.575.000 | -2,70 pp | |
| 17.02.2026 | Vestal Point Capital, LP | Passiv (13G/A) | 6,50 % | 3.575.000 | -2,70 pp | |
| 12.02.2026 | David Kroin | Passiv (13G) | 5,02 % | 2.750.000 | Neu | |
| 12.02.2026 | Deep Track Biotechnology Master Fund, Ltd. | Passiv (13G) | 5,02 % | 2.750.000 | Neu | |
| 12.02.2026 | Deep Track Capital, LP | Passiv (13G) | 5,02 % | 2.750.000 | Neu | |
| 05.02.2026 | Abigail P. Johnson | Passiv (13G/A) | 6,10 % | 3.347.223 | +1,00 pp | |
| 05.02.2026 | FMR LLC | Passiv (13G/A) | 6,10 % | 3.347.223 | +1,00 pp | |
| 14.08.2025 | Ryan Wilder | Passiv (13G/A) | 9,20 % | 5.000.000 | +4,10 pp | |
| 14.08.2025 | Vestal Point Capital, LP | Passiv (13G/A) | 9,20 % | 5.000.000 | +4,10 pp | |
| 31.07.2025 | Siren, L.L.C. | Passiv (13G/A) | 8,90 % | 4.861.944 | +3,30 pp | |
| 31.07.2025 | Avicenna Life Sci Master Fund LP | Passiv (13G/A) | 0,70 % | 355.025 | +0,60 pp | |
| 31.07.2025 | Avicenna Life Sci Master GP LLC | Passiv (13G/A) | 0,70 % | 355.025 | +0,60 pp | |
| 31.07.2025 | Invus Global Management, LLC | Passiv (13G/A) | 8,90 % | 4.861.944 | +3,30 pp | |
| 31.07.2025 | Invus Public Equities Advisors, LLC | Passiv (13G/A) | 8,90 % | 4.861.944 | +3,30 pp | |
| 31.07.2025 | Invus Public Equities, L.P. | Passiv (13G/A) | 8,90 % | 4.861.944 | +3,30 pp | |
| 31.07.2025 | Raymond Debbane | Passiv (13G/A) | 9,60 % | 5.216.969 | +3,90 pp | |
| 31.07.2025 | Ulys, L.L.C. | Passiv (13G/A) | 0,70 % | 355.025 | +0,60 pp | |
| 17.07.2025 | FMR LLC | Passiv (13G) | 5,10 % | 2.756.217 | +0,40 pp | |
| 17.07.2025 | Abigail P. Johnson | Passiv (13G) | 5,10 % | 2.756.217 | +0,40 pp | |
| 17.07.2025 | FMR LLC | Passiv (13G/A) | 4,70 % | 2.538.404 | -1,90 pp | |
| 17.07.2025 | Abigail P. Johnson | Passiv (13G/A) | 4,70 % | 2.538.404 | -1,90 pp | |
| 15.05.2025 | Vestal Point Capital, LP | Passiv (13G) | 5,10 % | 2.768.975 | Neu | |
| 15.05.2025 | Ryan Wilder | Passiv (13G) | 5,10 % | 2.768.975 | Neu |
Stammdaten
Bicara Therapeutics Inc. ist ein klinisches Biopharmazie-Unternehmen, das bifunktionelle Therapien für solide Tumoren entwickelt. Das Hauptprogramm ist ficerafusp alfa, ein bifunktionaler Antikörper, der einen auf den epidermalen Wachstumsfaktor-Rezeptor (EGFR) gerichteten monoklonalen Antikörper mit einer Domäne kombiniert, die an den humanen transformierenden Wachstumsfaktor Beta (TGF-β) bindet, zur Behandlung solider Tumoren. Das Unternehmen wurde 2018 gegründet und hat seinen Sitz in Boston, Massachusetts. Bicara Therapeutics Inc. ist eine Tochtergesellschaft von Biocon Limited.
Unternehmen & Branche
| Name | Bicara Therapeutics Inc. |
|---|---|
| Ticker | BCAX |
| CIK | 0002023658 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 055477103 |
|---|---|
| ISIN | US0554771032 |
| Typ | Common Stock |
| Marktkapitalisierung | 1,20 Mrd. USD |
Bewertung
| KBV (P/B) | 3,00 |
|---|---|
| FCF-Rendite | -8,9 % |
Qualität & Bilanz
| ROIC | -34,2 % |
|---|
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2023. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|
| Bewertung | ||||
| KBV (P/B) | – | 1,93 | 2,37 | |
| FCF-Rendite | – | -7,9 % | -11,2 % | |
| Qualität & Bilanz | ||||
| ROIC | – | -13,8 % | -34,2 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | -56.211.000 | -0,93 | 553.599.000 | 513.958.000 | |
| 2025-12-31 | 10-K | -137.950.000 | -2,52 | 430.994.000 | 401.452.000 | |
| 2025-09-30 | 10-Q | -36.330.000 | -0,67 | 424.688.000 | 402.780.000 | |
| 2025-06-30 | 10-Q | -27.388.000 | -0,50 | 453.587.000 | 435.196.000 | |
| 2025-03-31 | 10-Q | -36.846.000 | -0,68 | 478.077.000 | 458.957.000 | |
| 2024-12-31 | 10-K | -67.995.000 | -4,05 | 509.996.000 | 491.875.000 | |
| 2024-09-30 | 10-Q | -17.481.000 | -1,60 | 524.173.000 | 509.555.000 | |
| 2024-06-30 | 10-Q | -17.049.000 | -19,01 | -174.776.000 | ||
| 2024-03-31 | 10-Q | -12.508.000 | -18,94 | -160.080.000 | ||
| 2023-12-31 | 10-K | -51.985.000 | -89,61 | 233.982.000 | -148.769.000 | |
| 2023-09-30 | 10-Q | -22.845.000 | -38,23 | -137.111.000 | ||
| 2023-06-30 | 10-Q | -9.288.000 | -114.817.000 | |||
| 2023-03-31 | 10-Q | -7.412.000 | -105.908.000 |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 11.05.2026 | – | -0,93 |
| Q3 2025 | 30.09.2025 | 10.11.2025 | – | -0,67 |
| Q2 2025 | 30.06.2025 | 10.11.2025 | – | -0,50 |
| Q1 2025 | 31.03.2025 | 11.05.2026 | – | -0,68 |
| Q3 2024 | 30.09.2024 | 10.11.2025 | – | -1,60 |
| Q2 2024 | 30.06.2024 | 10.11.2025 | – | -19,01 |
| Q1 2024 | 31.03.2024 | 10.11.2025 | – | -18,94 |
| Q3 2023 | 30.09.2023 | 12.11.2024 | – | -38,23 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 11.05.2026 | 10-Q | 31.03.2026 | 41 Tage | SEC » |
| 30.03.2026 | 10-K | 31.12.2025 | 89 Tage | SEC » |
| 10.11.2025 | 10-Q | 30.09.2025 | 41 Tage | SEC » |
| 12.08.2025 | 10-Q | 30.06.2025 | 43 Tage | SEC » |
| 13.05.2025 | 10-Q | 31.03.2025 | 43 Tage | SEC » |
| 27.03.2025 | 10-K | 31.12.2024 | 86 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-05-08 | 21.400 | 23,09 | 494.126 |
| 2026-04-29 | 81 | 21,92 | 1.776 |
| 2026-04-28 | 2.498 | 22,48 | 56.155 |
| 2026-04-17 | 922 | 23,93 | 22.063 |
| 2026-04-14 | 747 | 22,14 | 16.539 |
| 2026-04-09 | 599 | 21,61 | 12.944 |
| 2026-04-06 | 10.004 | 21,47 | 214.786 |
| 2026-04-02 | 2.863 | 20,50 | 58.692 |
| 2026-03-31 | 22 | 19,04 | 419 |
| 2026-03-30 | 783 | 18,37 | 14.384 |
| 2026-03-27 | 955 | 18,92 | 18.069 |
| 2026-03-26 | 1.488 | 18,68 | 27.796 |
| 2026-03-24 | 8 | 18,39 | 147 |
| 2026-03-20 | 4.946 | 18,79 | 92.935 |
| 2026-03-17 | 113.444 | 19,40 | 2.200.814 |
| 2026-03-16 | 120 | 19,19 | 2.303 |
| 2026-03-13 | 812 | 19,21 | 15.599 |
| 2026-03-12 | 2.261 | 19,90 | 44.994 |
| 2026-03-11 | 100.235 | 20,06 | 2.010.714 |
| 2026-03-10 | 30.623 | 19,70 | 603.273 |
| 2026-03-09 | 260 | 18,47 | 4.802 |
| 2026-03-06 | 1.043 | 18,50 | 19.296 |
| 2026-03-05 | 3.082 | 18,54 | 57.140 |
| 2026-03-04 | 2 | 17,92 | 36 |
| 2026-02-26 | 2.161 | 17,51 | 37.839 |
| 2026-02-18 | 1.562 | 14,08 | 21.993 |
| 2026-02-12 | 20.057 | 14,80 | 296.844 |
| 2026-02-06 | 30.015 | 15,10 | 453.227 |
| 2026-02-05 | 25.000 | 16,37 | 409.250 |
| 2026-02-04 | 585 | 17,01 | 9.951 |
| 2026-02-02 | 1.357 | 16,80 | 22.798 |
| 2026-01-30 | 1.421 | 16,91 | 24.029 |
| 2026-01-29 | 348 | 16,59 | 5.773 |
| 2026-01-28 | 114 | 16,77 | 1.912 |
| 2026-01-23 | 5.687 | 17,59 | 100.034 |
| 2026-01-21 | 6.569 | 16,72 | 109.834 |
| 2026-01-14 | 1.624 | 17,53 | 28.469 |
| 2026-01-08 | 1.252 | 17,17 | 21.497 |
| 2026-01-06 | 2.876 | 16,11 | 46.332 |
| 2025-12-31 | 104 | 16,12 | 1.676 |
| 2025-12-24 | 4.329 | 17,55 | 75.974 |
| 2025-12-23 | 14.643 | 18,32 | 268.260 |
| 2025-12-22 | 227 | 17,60 | 3.995 |
| 2025-12-17 | 5.496 | 18,15 | 99.752 |